最新ニュース Meituan (OTC:MPNGY) 株価情報

Meituan is the largest food delivery platform in China, with a 60%-70% share of the market in 2024, according to Morningstar estimates. In the third quarter of 2024, the firm generated 74% of its revenue from the core local commerce segment, which includes on-demand food delivery and retail, in-store services (such as visiting beauty and entertainment stores after purchasing deals on Meituan), as well as hotel and travel booking. The remaining 26% of revenue came from the new initiatives segment, such as from the community group purchase business Meituan Select and the overseas food delivery business.

Meituan

Byline Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BY#NYSE">BY</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.61 by 4.92 percent. This is a 8.57 percent decrease over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $103.08 million which beat the analyst consensus estimate of $100.82 million by 2.24 percent. This is a 2.05 percent increase over sales of $101.01 million the same period last year.

Earnings

Earnings Beats

News

Byline Bancorp Q1 Adj. EPS $0.64 Beats $0.61 Estimate, Sales $103.08M Beat $100.82M Estimate

NBT Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.74 by 8.11 percent. This is a 17.65 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $154.68 million which beat the analyst consensus estimate of $151.05 million by 2.40 percent. This is a 10.04 percent increase over sales of $140.57 million the same period last year.

NBTB

NBT Bancorp Q1 Adj. EPS $0.80 Beats $0.74 Estimate, Sales $154.68M Beat $151.05M Estimate

Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.92 by 19.57 percent. This is a 23.6 percent increase over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $423.54 million which beat the analyst consensus estimate of $422.05 million by 0.35 percent. This is a 6.85 percent increase over sales of $396.37 million the same period last year.

Federated Hermes Q1 Adj. EPS $1.10 Beats $0.92 Estimate, Sales $423.54M Beat $422.05M Estimate

General

SES AI Authorizes Repurchase Up To $30M Of Its Class A Common Stock

First Western Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.23 by 86.96 percent. This is a 65.38 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $24.80 million which beat the analyst consensus estimate of $24.10 million by 2.88 percent. This is a 6.21 percent increase over sales of $23.35 million the same period last year.

MYFW

First Western Financial Q1 EPS $0.43 Beats $0.23 Estimate, Sales $24.80M Beat $24.10M Estimate

Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.48 by 52.08 percent. This is a 88.44 percent decrease over earnings of $1.99 per share from the same period last year. The company reported quarterly sales of $382.39 million which missed the analyst consensus estimate of $400.60 million by 4.55 percent. This is a 22.26 percent decrease over sales of $491.91 million the same period last year.

Earnings Misses

Universal Logistics Hldgs Q1 EPS $0.23 Misses $0.48 Estimate, Sales $382.39M Miss $400.60M Estimate

Middlefield Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBCN#NASDAQ">MBCN</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.46 by 30.43 percent. This is a 17.65 percent increase over earnings of $0.51 per share from the same period last year.

MBCN

Middlefield Banc Q1 EPS $0.60 Beats $0.46 Estimate

World Kinect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WKC#NYSE">WKC</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.45 by 6.67 percent. This is a 2.13 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $9.45 billion which missed the analyst consensus estimate of $10.47 billion by 9.73 percent. This is a 13.68 percent decrease over sales of $10.95 billion the same period last year.

World Kinect Q1 Adj. EPS $0.48 Beats $0.45 Estimate, Sales $9.45B Miss $10.47B Estimate

Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) narrows FY2025 FFO guidance from $3.83-$3.88 to $3.84-$3.87 vs $3.89 analyst estimate..

Guidance

GLPI

Gaming and Leisure Props Narrows FY2025 FFO Guidance from $3.83-$3.88 to $3.84-$3.87 vs $3.89 Est

Eastman Chemical Q1 Adj. EPS $1.91 Beats $1.89 Estimate, Sales $2.29B Miss $2.33B Estimate

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced Thursday that it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">the next four years</a>.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44976531/thermo-fisher-scientific-invests-to-enhance-u-s-innovation-and-support-customers-manufacturing" rel="noreferrer noopener">medicines in America</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
These additional investments to the company&#8217;s American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes:
<ul>
<li>$1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations</li>
<li>Complemented by $500 million in R&amp;D focused on high-impact innovation</li>
</ul>
Thermo Fisher CEO Marc N. Casper explained that by expanding in the U.S., the company ensures that &#8220;life-saving medicines and therapies will continue to be developed and produced in America for decades to come.&#8221;
This investment builds on Thermo Fisher&#8217;s 64 U.S. manufacturing operations in 37 states.
The company also invests $1 billion annually in R&amp;D in the U.S.
Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.
On Wednesday, Thermo Fisher said that it expects U.S.-China tariffs to hurt sales in China for products made in the U.S. The company estimates this will reduce revenue by $400 million in 2025. These tariffs will also raise the cost of parts and subassemblies <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966173/thermo-fisher-beats-q1-estimates-lowers-full-year-forecast-as-tariffs-and-costs-take-a-toll" rel="noreferrer noopener">sourced from China</a>.
After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a $375 million hit compared to previous guidance.
Analyst Reactions on Thursday:
<ul>
<li>Baird maintains Thermo Fisher Scientific with an Outperform, lowering the price target from $603 to $573.</li>
<li>Wells Fargo maintains Thermo Fisher with an Overweight rating and lowers the price target from $580 to $570.</li>
<li>Evercore ISI maintains Thermo Fisher with an Outperform, lowering the price target from $585 to $500.</li>
<li>Stifel reaffirms the Buy rating for Thermo Fisher, lowering the price target from $665 to $620.</li>
</ul>
Price Action: TMO stock is down 2.57% at $420.55 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" target="_blank" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan

Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) reported quarterly earnings of $0.96 per share which met the analyst consensus estimate. This is a 4.35 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $395.24 million which missed the analyst consensus estimate of $396.52 million by 0.32 percent. This is a 5.13 percent increase over sales of $375.96 million the same period last year.

Gaming and Leisure Props Q1 FFO $0.96, Inline, Sales $395.24M Miss $396.52M Estimate

Dividends

GOOG

GOOGL

Alphabet Raises Quarterly Dividend From $0.20 To $0.21 Per Share

WIIM

Alphabet shares are trading higher following better-than-expected Q1 financial results.

Rosenblatt analyst Catharine Trebnick maintained a Buy rating on Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) on Thursday,<a href="https://www.benzinga.com/quote/ZM/analyst-ratings" target="_blank" rel="noreferrer noopener"> lowering the price forecast from $95 to $90.</a>
Trebnick cautioned about growing macroeconomic uncertainty and potential tariff-related challenges that may hinder the company&#8217;s ability to expand revenue streams beyond the U.S. market.
The new forecast reflects a valuation of approximately 4.2 times the projected 2027 revenue, down from the previous multiple of 4.5 times.
While Zoom is trading at 3.0 times its enterprise value to estimated 2027 sales—a level consistent with the broader SaaS group average—it is growing revenue at 3% year over year, compared to the group&#8217;s 6%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44965915/northrop-grummans-strategic-edge-lies-in-classified-space-and-electronic-warfare-programs-but-market-focused-on-short-term-issues-analyst" rel="noreferrer noopener">Northrop Grumman&#8217;s Flight Path Recalculated: Analyst Trims Forecast, Reiterates Buy</a>
However, the analyst notes that this valuation is still reasonable given Zoom&#8217;s strong financial footing, including a substantial $7.8 billion cash reserve and a free cash flow margin of 37%, which significantly exceeds the industry average of 26%.
Trebnick trimmed the revenue growth expectations for Zoom, now forecasting a 2.2% increase for FY26—below the company&#8217;s FY25 guidance of 2.7% at the midpoint.
For FY25, the analyst estimates revenue at $4.768 billion, reflecting 2.6% growth and slightly below both their previous estimate and the Street consensus of $4.788 billion.
FY27 revenue is also adjusted downward to $4.935 billion, implying 3.5% growth and again falling short of the consensus estimate of $4.949 billion.
As a result of these lower projections, adjusted operating income for FY25 is revised to $1.854 billion with a margin of 38.9%, just under the Street&#8217;s forecast, Trebnick writes.
Due to reduced sales volume expectations, the analyst now projects FY26 pro forma EPS at $5.34, unchanged from their previous estimate.
Looking further ahead, with anticipated revenue growth of just 3.5% in FY27, the EPS forecast has been modestly lowered to $5.48 from $5.50, the analyst writes.
Price Action: ZM shares are trading higher by 3.16% to $75.28 at last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44962890/3-key-signals-say-its-time-to-invest-in-this-forgotten-market-heres-how" target="_blank" rel="noreferrer noopener">3 Key Signals Say It&#8217;s Time To Invest In This &#8216;Forgotten&#8217; Market, Here&#8217;s How</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Zoom Faces International Growth Risks Amid Macroeconomic And Tariff Headwinds: Analyst

Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) has outperformed the market over the past 15 years by 2.78% on an annualized basis producing an average annual return of 13.49%. Currently, Accenture has a market capitalization of $182.56 billion. 
Buying $100 In ACN: If an investor had bought $100 of ACN stock 15 years ago, it would be worth $659.45 today based on a price of $291.41 for ACN at the time of writing.
<h3>Accenture's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745525714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.27 by 3.94 percent. This is a 26.92 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $33.30 million which missed the analyst consensus estimate of $40.13 million by 17.01 percent. This is a 8.20 percent decrease over sales of $36.28 million the same period last year.

FBIZ

First Business Finl Servs Q1 EPS $1.32 Beats $1.27 Estimate, Sales $33.30M Miss $40.13M Estimate

Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) reported quarterly losses of $(0.06) per share. This is a 90 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $40.74 million which beat the analyst consensus estimate of $16.30 million by 149.97 percent. This is a 0.84 percent decrease over sales of $41.09 million the same period last year.

GNFT

Genfit FY EPS $(0.06) Up From $(0.62) YoY, Sales $40.74M Beat $16.30M Estimate

Universal Insurance Hldgs Q1 Adj. EPS $1.44 Beats $1.26 Estimate, Sales $394.87M Beat $354.97M Estimate

Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) has been tapped by defense contractor Kratos Defense &amp; Security Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) to carry out a <a href="https://www.benzinga.com/pressreleases/25/04/b44965385/rocket-lab-awarded-new-haste-launch-contract-for-the-dod-by-kratos">hypersonic flight test </a>for the U.S. Department of Defense as part of the MACH-TB 2.0 program.
The mission, set to occur no sooner than early 2026, will lift off from Rocket Lab's Launch Complex 2 located on Wallops Island, Virginia. 
It represents the initial full-scale test flight granted by Kratos through the $1.45 billion MACH-TB 2.0 initiative, aimed at accelerating the development and evaluation of hypersonic technologies.
Also Read: <a href="https://www.benzinga.com//node/44629352">Rocket Lab Unveils Advanced Space-Grade Radios For Deep Space Missions</a>
Rocket Lab joined the MACH-TB 2.0 roster in January, following its successful support of multiple hypersonic tests under the original MACH-TB program in 2023. 
The company previously executed three missions for the Department of Defense, two of which launched just three weeks apart from the same Virginia site.
&#8220;In less than two years since its first launch, HASTE has quickly emerged as a leading commercial test platform of hypersonic systems. With our operational speed and cadence, and the ability to serve multiple mission profiles all in one platform, HASTE is helping to move the needle on hypersonic innovation,&#8221; said founder and CEO Sir Peter Beck.
For the upcoming test, Rocket Lab will deploy its HASTE launch vehicle, a suborbital adaptation of the company's Electron rocket. 
Designed for high-speed performance and flexible payload capacity, HASTE features lightweight carbon composite construction, additively manufactured engines, and a reconfigured Kick Stage tailored to support larger hypersonic experiment loads. 
The rocket can propel test systems at speeds exceeding 7.5 kilometers per second, allowing trials of air-breathing propulsion, glide bodies, and atmospheric reentry systems.
Beyond the MACH-TB program, HASTE has been added to several international defense frameworks. It is now listed under the <a href="https://www.benzinga.com/25/04/44814484/rocket-lab-stock-is-ripping-higher-tuesday-heres-why">U.S. Air Force's $46 billion Enterprise-Wide Agile Acquisition Contract</a> (EWAAC), granting Rocket Lab eligibility to compete for further defense-related launch services.
Price Action: RKLB shares traded higher by 8.21% at $21.96 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44990084/taiwan-semiconductor-to-begin-production-of-14-nm-chips-in-2028-enhancing-ai-and-smartphone-performance">Taiwan Semiconductor To Begin Production Of Advanced 1.4nm Chips In 2028</a></li>
</ul>

Comments

Meituan

ニュース

最新ニュース Meituan (OTC:MPNGY) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル